Literature DB >> 15824986

Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment.

Michael P Busch, Kimberly A Page Shafer.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15824986     DOI： 10.1086/428583

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  13 in total

Review 1.  Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C.

Authors:  Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

2.  Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.

Authors:  Heidi Barth; Jolanta Rybczynska; Romuald Patient; Youkyung Choi; Ronda K Sapp; Thomas F Baumert; Kris Krawczynski; T Jake Liang
Journal:  Hepatology       Date:  2011-08-11       Impact factor: 17.425

3.  Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

Authors:  Behzad Hajarizadeh; Bart Grady; Kimberly Page; Arthur Y Kim; Barbara H McGovern; Andrea L Cox; Thomas M Rice; Rachel Sacks-Davis; Julie Bruneau; Meghan Morris; Janaki Amin; Janke Schinkel; Tanya Applegate; Lisa Maher; Margaret Hellard; Andrew R Lloyd; Maria Prins; Ronald B Geskus; Gregory J Dore; Jason Grebely
Journal:  J Clin Virol       Date:  2014-09-08       Impact factor: 3.168

4.  Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

Authors:  B Hajarizadeh; B Grady; K Page; A Y Kim; B H McGovern; A L Cox; T M Rice; R Sacks-Davis; J Bruneau; M Morris; J Amin; J Schinkel; T Applegate; L Maher; M Hellard; A R Lloyd; M Prins; R B Geskus; G J Dore; J Grebely
Journal:  J Viral Hepat       Date:  2015-01-08       Impact factor: 3.728

5.  High levels of subgenomic HCV plasma RNA in immunosilent infections.

Authors:  Flavien Bernardin; Susan L Stramer; Barbara Rehermann; Kimberly Page-Shafer; Stewart Cooper; David R Bangsberg; Judith Hahn; Leslie Tobler; Michael Busch; Eric Delwart
Journal:  Virology       Date:  2007-05-09       Impact factor: 3.616

6.  Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates.

Authors:  Kimberly Page-Shafer; Brandee L Pappalardo; Leslie H Tobler; Bruce H Phelps; Brian R Edlin; Andrew R Moss; Teresa L Wright; David J Wright; Thomas R O'Brien; Sally Caglioti; Michael P Busch
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

7.  Immiscible phase filter extraction and equivalent amplification of genotypes 1-6 of hepatitis C RNA: The building blocks for point-of-care diagnosis.

Authors:  Mário F Neto; Matthew A Butzler; Jennifer L Reed; Xiang Rui; Mark J Fisher; David M Kelso; Sally M McFall
Journal:  J Virol Methods       Date:  2017-06-30       Impact factor: 2.014

8.  Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys.

Authors:  L Leon; S Kasereka; F Barin; C Larsen; L Weill-Barillet; X Pascal; S Chevaliez; J Pillonel; M Jauffret-Roustide; Y LE Strat
Journal:  Epidemiol Infect       Date:  2016-12-22       Impact factor: 4.434

9.  Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a.

Authors:  Noha Sharaf Eldin; Soheir Ismail; Hala Mansour; Claire Rekacewicz; Moustafa El-Houssinie; Sherif El-Kafrawy; Saeed El Aidi; Mohamed Abdel-Hamid; Gamal Esmat; Stanislas Pol; Arnaud Fontanet; Mostafa K Mohamed
Journal:  PLoS One       Date:  2008-12-30       Impact factor: 3.240

10.  A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients.

Authors:  Sadia Qamar Arain; Farah Naz Talpur; Naseem Aslam Channa
Journal:  Lipids Health Dis       Date:  2015-09-24       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.